Duration of Initial Intensive Rivaroxaban Therapy for Patients With Venous Thromboembolism　― Subanalysis of the J’xactly Study ―

Background: Rivaroxaban, a direct oral anticoagulant, is used as a first-line treatment to prevent venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). However, whether 21 days is optimal for the initial treatment duration has not been investigated. Methods...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Mashio, Fukuda, Ikuo, Yamada, Norikazu, Takayama, Morimasa, Maeda, Hideaki, Yamashita, Takeshi, Ikeda, Takanori, Mo, Makoto, Yamazaki, Tsutomu, Okumura, Yasuo, Hirayama, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Circulation Society 2023
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072900/
https://www.ncbi.nlm.nih.gov/pubmed/37025939
http://dx.doi.org/10.1253/circrep.CR-23-0008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072900/
https://www.ncbi.nlm.nih.gov/pubmed/37025939
http://dx.doi.org/10.1253/circrep.CR-23-0008

Ejemplares similares